Leave a request
Virta Health announced that a study of its diabetes progression prevention treatment proved more effective than initially expected.
Peer-reviewed research in Nutrients highlighted the fact that only 3% of trial participants progressed to Type 2 diabetes, while over half achieved prediabetes reversal during the first two years, according to a news release.
Additionally, the trial observed 75% of patients retained at the two-year mark. Virta Health said the figures “far exceed” outcomes reported for the National Institutes of Health Diabetes Prevention Program (NIH DPP) and its real-world translation, the National Diabetes Prevention Program (NDPP), which is considered the “gold standard” in the prediabetes treatment space.
Virta observed 52% of patients achieve prediabetes reversal, while the company’s patients also experienced average weight loss of 11.3% at two years, more than doubling the NDPP’s 5% goal for prediabetes. While NDPP’s one-year retention was 13.2%, Virta’s was 80%, dropping to 75% at two years.
Virta Health launched in 2017 with a goal of reversing Type 2 diabetes using its technology platform to enable personalized remote care. The company provides physician supervision, health coaches, an app and biomarker tracking tools, as well as a personalized nutrition plan for its patients in the hopes of reversing Type 2 diabetes. According to the company, in clinical studies, 94% of its patients reduce or eliminate insulin use.
Based on: DrugDeliveryBusiness
#News #Health #Medical #VirtaHealth #Whealthnews
Leave a request